Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle

被引：3

作者：

LaBonte, Melissa J. ^{[1
]}

Lenz, Heinz-Josef ^{[2
]}

机构：

[1] Azusa Pacific Univ, Dept Biol & Chem, Azusa, CA USA

[2] Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90033 USA

来源：

PHARMACOGENOMICS | 2013年 / 14卷 / 14期

关键词：

5-FU; apoptosis; CDK inhibitors; cell cycle; colorectal cancer; cyclin D; DNA damage; polymorphism; thymidylate synthase; CELL-CYCLE; EXPRESSION; D1B;

D O I：

10.2217/pgs.13.138

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

引用

页码：1671 / 1674

页数：4

共 18 条

[1]

The cyclin D1 (CCND1) rs9344 G > A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy [J].

Absenger, G. ;

Benhaim, L. ;

Szkandera, J. ;

Zhang, W. ;

Yang, D. ;

Labonte, M. J. ;

Pichler, M. ;

Stotz, M. ;

Samonigg, H. ;

Renner, W. ;

Gerger, A. ;

Lenz, H-J .

PHARMACOGENOMICS JOURNAL, 2014, 14 (02) :130-134

[2]

Phase II study of flavopiridol in patients with advanced colorectal cancer [J].

Aklilu, M ;

Kindler, HL ;

Donehower, RC ;

Mani, S ;

Vokes, EE .

ANNALS OF ONCOLOGY, 2003, 14 (08) :1270-1273

[3]

Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner [J].

Chung, Heekyung ;

Chaudhry, Joy ;

Lopez, Claudia G. ;

Carethers, John M. .

CANCER BIOLOGY & THERAPY, 2010, 10 (11) :1148-1157

[4]

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer [J].

Flaherty, Keith T. ;

LoRusso, Patricia M. ;

DeMichele, Angela ;

Abramson, Vandana G. ;

Courtney, Rachel ;

Randolph, Sophia S. ;

Shaik, M. Naveed ;

Wilner, Keith D. ;

O'Dwyer, Peter J. ;

Schwartz, Gary K. .

CLINICAL CANCER RESEARCH, 2012, 18 (02) :568-576

[5]

Guo XX, 2008, ANTICANCER RES, V28, P9

[6]

Cell-cycle checkpoints and cancer [J].

Kastan, MB ;

Bartek, J .

NATURE, 2004, 432 (7015) :316-323

[7]

The cyclin D1b splice variant: an old oncogene learns new tricks [J].

Knudsen, Karen E. .

CELL DIVISION, 2006, 1 (1)

[8]

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer [J].

LaBonte, M. J. ;

Wilson, P. M. ;

Yang, D. ;

Zhang, W. ;

Ladner, R. D. ;

Ning, Y. ;

Gerger, A. ;

Bohanes, P. O. ;

Benhaim, L. ;

El-khoueiry, R. ;

El-khoueiry, A. ;

Lenz, H. -J. .

ANNALS OF ONCOLOGY, 2012, 23 (06) :1455-1464

[9]

Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response [J].

Li, Zhiping ;

Jiao, Xuanmao ;

Wang, Chenguang ;

Shirley, L. Andrew ;

Elsaleh, Hany ;

Dahl, Olav ;

Wang, Min ;

Soutoglou, Evi ;

Knudsen, Erik S. ;

Pestell, Richard G. .

CANCER RESEARCH, 2010, 70 (21) :8802-8811

[10]

5-Fluorouracil: Mechanisms of action and clinical strategies [J].

Longley, DB ;

Harkin, DP ;

Johnston, PG .

NATURE REVIEWS CANCER, 2003, 3 (05) :330-338

← 1 2 →